Key clinical point: Progression-free survival was better with A+AVD (brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine) than with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) as frontline treatment in patients with stage III or IV Hodgkin lymphoma.
Major finding: The 3-year progression-free survival rate was significantly higher in the A+AVD arm than in the ABVD arm – 83.1% and 76.0%, respectively (HR, 0.704; P = .005).
Study details: An update of ECHELON-1, a phase 3 trial of 1,334 patients with stage III or IV Hodgkin lymphoma.
Disclosures: The trial was sponsored by Millennium Pharmaceuticals (a subsidiary of Takeda) and Seattle Genetics. The investigators disclosed relationships with Millennium, Takeda, Seattle Genetics, and a range of other companies.
Straus DJ et al. Blood. 2020 Jan 16. pii: blood.2019003127. doi: 10.1182/blood.2019003127.